Development and evaluation of a cetuximab-based imaging probe to target EGFR and EGFRvIII

Abstract Background and purpose The epidermal growth factor receptor (EGFR) is overexpressed in a significant percentage of human malignancies and its expression is associated with tumour aggressiveness and treatment resistance. The monoclonal antibody cetuximab (IMC-C225) blocks the ligand-binding...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Radiotherapy and oncology 2007-06, Vol.83 (3), p.326-332
Hauptverfasser:	Aerts, Hugo J.W.L, Dubois, Ludwig, Hackeng, Tilman M, Straathof, Roel, Chiu, Roland K, Lieuwes, Natasja G, Jutten, Barry, Weppler, Sherry A, Lammering, Guido, Wouters, Bradly G, Lambin, Philippe
Format:	Artikel
Sprache:	eng
Schlagworte:	Animals Antibodies, Monoclonal - chemistry Antibodies, Monoclonal - pharmacokinetics Antibodies, Monoclonal, Humanized Antineoplastic Agents - chemistry Antineoplastic Agents - pharmacokinetics Carboxylic Acids - chemistry Cell Line, Tumor Cetuximab Drug Delivery Systems EGFR EGFRvIII Flow Cytometry Fluorescent Antibody Technique Fluorescent Dyes - chemistry Fluorescent Dyes - pharmacokinetics Hematology, Oncology and Palliative Medicine Humans Imaging probe evaluation Mice Mice, Nude Neoplasms - diagnosis Neoplasms - drug therapy Neoplasms - metabolism Receptor, Epidermal Growth Factor - analysis Receptor, Epidermal Growth Factor - antagonists & inhibitors Receptor, Epidermal Growth Factor - metabolism Xenograft Model Antitumor Assays
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!